Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of the Safety and Efficacy of 1% and 2% Pilocarpine Ophthalmic Solutions Administered With the Optejet Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia

Next Previous
Search
Trial Profile

A Phase 3 Study of the Safety and Efficacy of 1% and 2% Pilocarpine Ophthalmic Solutions Administered With the Optejet Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pilocarpine (Primary)
  • Indications Presbyopia
  • Focus Registrational; Therapeutic Use
  • Acronyms VISION-1
  • Sponsors Eyenovia

    • Most Recent Events

    • 11 May 2023 According to an Eyenovia media release, the company received the feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and efficient path forward for the program.
    • 27 Jul 2022 According to an Eyenovia media release, NDA submission anticipated in 2023.
    • 05 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top